Post by c2crusher on Mar 2, 2021 2:32:33 GMT
content.equisolve.net/_f5673026aa2f11a581b8bf5499c781b0/cocrystalpharma/db/102/379/pdf/COCP+Investor+Presentation+-+030121+final+March.pdf
COVID-19 Program Status
• Potential to be effective treatment for COVID-19
• Develop SARS-CoV-2 inhibitors using proprietary platform technology
• Targeting viral replication complex and protease
• Potential first-in-class therapeutic and prophylactic treatment
Achieved Milestones and Next Steps:
✓ Q2 2020 Filed Additional Patent Application
✓ Q2 2020 Proof-of-Concept Animal Model Study
✓ Q2 2020 Initiated Preclinical Studies of COVID-19 Inhibitors
✓ Q3 2020 Identified Additional Inhibitors Using Cocrystal Proprietary Platform Technology
✓ Q4 2020 CDI-45205 Selected as Preclinical Lead from KSURF-licensed inhibitors
• 2021 Working toward pre-IND status with CDI-45205
• 2021 Develop additional COVID-19 Inhibitors with novel mechanism of action
Financial Snapshot
• Clean balance sheet
• No preferred shares
• No debt
• Only 243,000 warrants
• ~$800,000/month 2021 cash burn
• Cash runway beyond 2022
COVID-19 Program Status
• Potential to be effective treatment for COVID-19
• Develop SARS-CoV-2 inhibitors using proprietary platform technology
• Targeting viral replication complex and protease
• Potential first-in-class therapeutic and prophylactic treatment
Achieved Milestones and Next Steps:
✓ Q2 2020 Filed Additional Patent Application
✓ Q2 2020 Proof-of-Concept Animal Model Study
✓ Q2 2020 Initiated Preclinical Studies of COVID-19 Inhibitors
✓ Q3 2020 Identified Additional Inhibitors Using Cocrystal Proprietary Platform Technology
✓ Q4 2020 CDI-45205 Selected as Preclinical Lead from KSURF-licensed inhibitors
• 2021 Working toward pre-IND status with CDI-45205
• 2021 Develop additional COVID-19 Inhibitors with novel mechanism of action
Financial Snapshot
• Clean balance sheet
• No preferred shares
• No debt
• Only 243,000 warrants
• ~$800,000/month 2021 cash burn
• Cash runway beyond 2022